Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma Clinical Trial

Official title:

Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06006117
• Other study ID #: MARSUN
• Status: Recruiting
• Phase: Phase 3
• Start date: September 5, 2023
• Est. completion date: September 2032

Study information

• Verified date: September 2023
• Source: The Lymphoma Academic Research Organisation
• Contact: Karima BRAHAMI
• Phone: 0634533784
• Email: karima.brahami-aissou[@]lysarc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.

The patients will be Randomized as follows:

Arm A - Experimental arm:

• Mosunetuzumab-Lenalidomide

Arm B - Comparator arms ( Investigator Choices):

• Rituximab-Lenalidomide

• Rituximab-Bendamustine

• Rituximab-CHOP

Description:

This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.

Patients are stratified according to MZL subtypes and time to progression of disease after first-line within 2 years (POD24) < 2 years or > 2 years.

Mosunetuzumab will be administered sub-cutaneously (SC) (21 days first cycle, then 28 days next cycles) and Lenalidomide will be given PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6. For each patient, investigator choice had to be decided before randomization between Rituximab-Lenalidomide and Rituximab-chemotherapy (R-Bendamustine or R-CHOP).

The primary efficacy endpoint for comparison is the Progression-free survival (PFS) as determined by investigator (Lugano criteria 2014). Secondary objectives include CR24 as determined by investigator (at 24 months) according to Lugano criteria 2014 and by central review based on PET result, Overall response rate (ORR) and CR other than CR24 as determined by investigator, or by central review based on PET result according to Lugano Criteria 2014. 260 patients are planned to be enrolled in France, Belgium, Germany, Italy and Portugal

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 260
• Est. completion date: September 2032
• Est. primary completion date: September 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Have a diagnosis of MZL, of extranodal (EMZL) or splenic (SMZL based on the Matutes score and CD20 + CD11c + CD180 + CD43 + CD200 expression and validated by a centralized review) or nodals (NMZL) subtypes. In case of large dissemination, disseminated MZL will be included as DMZL and included in NMZL subtype.

2. Have been treated with at least one prior systemic treatment and not more than three prior lines. Previous line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib (at least 1 month). Patients should not have received Lenalidomide before. Prior local therapy (including surgery, radiotherapy antibiotics for H. pylori-positive gastric lymphoma, and antiviral for hepatitis C virus) is not considered as one line of treatment

3. Signed Informed Consent Form

4. Age = 18 years at the time of signing the informed consent form

5. Ability to comply with the study protocol and procedures and required hospitalizations, in the investigator's judgement

6. Eastern Cooperative Oncology Group (ECOG) performance score (PS) of = 2

7. Have a symptomatic disease requiring a systemic treatment

8. Not eligible for a local treatment including radiotherapy or surgery

9. Stage I disease of EMZL, SMZL or NMZL may be eligible only if not candidate to local therapy (surgery or radiotherapy).

10. Measurable disease in at least two perpendicular dimensions on an imaging scan is defined as: lymph node or nodal mass bi-dimensional measurement with = 15 mm in longest transverse diameter or the short diameter must measure = 10 mm regardless of the longest transverse diameter.

Spleen is considered as a measurable disease if vertical axis is higher than 13 cm.

11. Adequate hematopoietic function at screening as follows unless cytopenia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune thrombocytopenia:

11.1. Platelet count = 75 G/L; in cases of thrombocytopenia clearly due to marrow involvement of MZL or hypersplenism or auto-immune thrombocytopenia, platelet count should be = 30 G/L Washout platelet transfusion is 7 days between transfusion and D1 of starting treatment 11.2. Absolute Neutrophil Count (ANC ) = 1 G/L unless neutropenia is clearly due to marrow involvement of MZL or hypersplenism. Granulocyte Colony-Stimulating Factor (G-CSF) is not allowed within 7 days before starting treatment 11.3. Total hemoglobin = 8 g/dL unless anemia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune hemolytic anemia. Washout erythrocyte transfusion is 7 days between transfusion and D1 of starting treatment

12. Serum total bilirubin = 1.5 x the upper limit of normal (ULN) (or =3 x ULN for patients with Gilbert syndrome),

13. Aspartate Transaminase (AST) or ALanine Transaminase (ALT) = 2.5 x ULN, unless directly attributable to the patient's MZL

14. Measured or estimated creatinine clearance = 40 mL/min by institutional standard method

15. Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation. Patients who are hepatitis B surface antigen (HBsAg) negative, hepatitis B surface antibody (anti-HBsAb) positive and hepatitis B core antibody (HBcAb) negative are eligible,

16. 16. Contraception: 16.1. For women of childbearing potential (WOCBP) (refer to section 14.6.1 and 14.6.1.1): Serum test pregnancy at screening and Day 1 before first dose. And then monthly until end of treatment. Efficient contraceptive method is required during the treatment period (including periods of treatment interruption), for at least 28 days after the final dose of Lenalidomide (if applicable), 3 months after the final dose of Mosunetuzumab (if applicable), 6 months after the final dose of chemotherapies (if applicable) and 12 months after the final dose of Rituximab (if applicable).

16.2. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period (including periods of treatment interruption), and for at least 28 days after the final dose of Lenalidomide (if applicable), 3 months after the final dose of Mosunetuzumab and Tocilizumab (if applicable), 6 months after the final dose of chemotherapies (if applicable) and 12 months after the final dose of Rituximab) (if applicable).

17. Patient covered by any social security system (France)

Exclusion Criteria:

1. MZL with histologic transformation to high-grade lymphoma

2. Pregnant or breastfeeding or intending to become pregnant during the study or within 28 days after the final dose of Lenalidomide, 3 months after the final dose of Mosunetuzumab and Tocilizumab (if applicable), 6 months after the final dose of chemotherapies and 12 months after the final dose of Rituximab (if applicable). Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.

3. Participants who have received any of the following treatments prior to study entry:

• Treatment with Mosunetuzumab or other CD20/CD3-directed bispecific antibodies

• Allogeneic stem cell transplant

4. Participants who have received any of the following treatments, whether investigational or approved, within the respective time periods prior to initiation of study treatment:

• Radiotherapy within 2 weeks prior to the first dose of study treatment

• Autologous stem cell transplant within 100 days prior to first study treatment

• Use of monoclonal antibodies within 4 weeks prior to first study treatment

• Systemic immunosuppressive medications (including, but not limited to, Cyclophosphamide, Azathioprine, Methotrexate, Thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to first dose of study treatment (C1D1); Systemic corticosteroid treatment <20 mg/day prednisone or equivalent and inhaled corticosteroids are permitted. Last dose of corticosteroid =20 mg/day prednisone or equivalent will not be permitted during the last 15 days before inclusion.

Administration of acute, low-dose, systemic immunosuppressant medications (e.g., single dose of 4 mg/day of dexamethasone for nausea or B-symptoms) is permitted during 4 days without washout.

• Any other anti-cancer investigational therapy within 4 weeks prior to initiation of study treatment.

5. Received a live, attenuated vaccine within 4 weeks before first dose of study treatment, or in whom it is anticipated that such a live attenuated vaccine will be required during the study period or within 5 months after the final dose of study treatment, except for acute pandemic situation such COVID19

6. Active or history of Central Nervous System (CNS) lymphoma or leptomeningeal infiltration

7. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins) - grade 3 and 4

8. Known hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the Mosunetuzumab, Rituximab, Tocilizumab, Lenalidomide, or Thalidomide formulation, including Mannitol

9. Patients unable to receive adequate prophylaxis and/or therapy for thromboembolic events (aspirin or low molecular weight heparin)

10. History of prior malignancy, except for conditions as listed below if patients have recovered from the acute side effects incurred as a result of previous therapy:

• Malignancies treated with curative intent and with no known active disease present for =2 years before enrollment

• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease

• Adequately treated cervical carcinoma in situ without evidence of disease

• Surgically/adequately treated low grade, early stage I, localized prostate in situ carcinoma

11. Participants with infections requiring IV treatment with antibiotics or hospitalization (Grade 3 or 4) within the last 4 weeks prior to inclusion or known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds),

12. Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to:

• Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure | American Heart Association)], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina)

• Significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)

• Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis

• Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed. Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible.

13. History of confirmed progressive multifocal leukoencephalopathy (PML)

14. Known Positive serologic HIV test at screening

15. Acute or chronic hepatitis C virus (HCV) infection Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation.

16. Known or suspected history of hemophagocytic lymphohistiocytosis

17. Known or suspected chronic active Epstein-Barr virus (EBV) infection within the last 4 weeks prior to inclusion

18. History of erythema multiforme, Grade =3 rash, or blistering following prior treatment with immunomodulatory derivatives

19. History of interstitial lung disease (ILD), drug-induced pneumonitis, and autoimmune pneumonitis

20. Active autoimmune disease requiring treatment

21. History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis; except:

• Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.

• Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.

• Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible.

• Patients with a remote history of, or well-controlled autoimmune disease, with a treatment-free interval from immunosuppressive therapy for 12 months may be eligible after review and discussion with the Medical Monitor.

22. Recent major surgery with risk of bleeding within 4 weeks prior to first study treatment administration (C1D1)

23. History of solid organ transplantation

24. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study

25. Person deprived of his/her liberty by a judicial or administrative decision

26. Person hospitalized without consent

27. Adult person under legal protection

28. Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

29. Patient unable to receive at least one of the three regimens of the comparator arm (ICT). As in usual practice, physician has to verify the absence of contraindication to the use of the drugs, hypersensitivity, and to take into account the lymphoma history and previous treatment scheme used.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• Marginal Zone Lymphoma

Intervention

Drug:
• Mosunetuzumab + Lenalidomide
Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles) C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15 C2 to C12: 45 mg D1 28-days cycles Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)
• - Rituximab + Lenalidomide (28-days cycles
Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6 Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
• - Rituximab + Bendamustine (28-days cycles)
Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion Rituximab* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6** (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). **For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6.
• - Rituximab + CHOP (21-days cycles)
CHOP, IV standard dose from cycle 1 to 6 Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)

Locations

Country	Name	City	State
France	CHU d'Amiens	Amiens
France	CH d'Avignon - Hopital Henri Duffaut	Avignon
France	CH de la Côte Basque - Hôpital de Bayonne	Bayonne
France	CHRU Besançon - Hôpital Minjoz	Besançon
France	Institut Bergonié	Bordeaux
France	Chu Estaing	Clermont Ferrand
France	CHU Henri Mondor	Créteil
France	CHU de Dijon	Dijon
France	CHU de Grenoble - Hôpital Albert Michallon	La Tronche
France	CHRU de LILLE - Claude Huriez	Lille
France	Institut Paoli Calmette	Marseille
France	CH Saint-Eloi	Montpellier
France	CHU de Nancy - Brabois	Nancy
France	Centre Catherine de Sienne	Nantes
France	CHU de Nantes - Hôtel Dieu	Nantes
France	Centre Antoine Lacassagne	Nice
France	CHU de Nice	Nice
France	CHR d'Orléans	Orleans
France	APHP - Hôpital Saint Louis	Paris Cedex 10
France	CHU Lyon Sud	Pierre-Bénite Cedex
France	CHU de Rennes - Hôpital de Pontchaillou	Rennes
France	Centre Henri Becquerel	Rouen
France	Institut de Cancérologie de la Loire Lucien Neuwirth	Saint-Priest-en-Jarez

Sponsors (1)

Lead Sponsor	Collaborator
The Lymphoma Academic Research Organisation

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS) as determined by investigator	according to Lugano criteria 2014	After 122 events = approximately 4.5 years and after 163 events = approximately 6.5 years (event = progression or death)
Secondary	Complete Response rate (CR) as determined by investigator (CR24)	according to Lugano criteria 2014	2 years
Secondary	Complete response rate (CR) by blinded central review (CR24)	based on PET result according to Lugano Criteria 2014	2 years
Secondary	Overall response rate (ORR) as determined by investigator	according to Lugano Criteria 2014	6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
Secondary	Overall response rate (ORR) as determined by investigator	according to Lugano Criteria 2014	12 months
Secondary	Overall response rate (ORR) as determined by investigator	according to Lugano Criteria 2014	24 months
Secondary	Overall response rate (ORR) as determined by investigator	according to Lugano Criteria 2014	36 months
Secondary	Overall response rate (ORR) as determined by investigator	according to Lugano Criteria 2014	48 months
Secondary	Overall response rate (ORR) as determined by investigator	according to Lugano Criteria 2014	60 months
Secondary	Overall response rate (ORR) by blinded central review	based on PET result according to Lugano Criteria 2014	6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
Secondary	Overall response rate (ORR) by blinded central review	based on PET result according to Lugano Criteria 2014	12 months
Secondary	Overall response rate (ORR) by blinded central review	based on PET result according to Lugano Criteria 2014	24 months
Secondary	Overall response rate (ORR) by blinded central review	based on PET result according to Lugano Criteria 2014	36 months
Secondary	Overall response rate (ORR) by blinded central review	based on PET result according to Lugano Criteria 2014	48 months
Secondary	Overall response rate (ORR) by blinded central review	based on PET result according to Lugano Criteria 2014	60 months
Secondary	CR rate other than CR24 as determined by investigator	according to Lugano Criteria 2014	6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
Secondary	CR rate other than CR24 as determined by investigator	according to Lugano Criteria 2014	12 months
Secondary	CR rate other than CR24 as determined by investigator	according to Lugano Criteria 2014	24 months
Secondary	CR rate other than CR24 as determined by investigator	according to Lugano Criteria 2014	36 months
Secondary	CR rate other than CR24 as determined by investigator	according to Lugano Criteria 2014	48 months
Secondary	CR rate other than CR24 as determined by investigator	according to Lugano Criteria 2014	60 months
Secondary	CR rate other than CR24 by blinded central review	based on PET result according to Lugano Criteria 2014	6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
Secondary	CR rate other than CR24 by blinded central review	based on PET result according to Lugano Criteria 2014	12 months
Secondary	CR rate other than CR24 by blinded central review	based on PET result according to Lugano Criteria 2014	24 months
Secondary	CR rate other than CR24 by blinded central review	based on PET result according to Lugano Criteria 2014	36 months
Secondary	CR rate other than CR24 by blinded central review	based on PET result according to Lugano Criteria 2014	48 months
Secondary	CR rate other than CR24 by blinded central review	based on PET result according to Lugano Criteria 2014	60 months
Secondary	Duration of response (DOR)		6.5 years
Secondary	Event-free survival (EFS)		6.5 years
Secondary	Time to next anti-lymphoma treatment (TTNLT)		6.5 years
Secondary	Histological transformation rate		6.5 years
Secondary	Safety: incidence and severity of Adverse Events (AE), of Serious Adverse Events (SAE), of Cytokine Release Syndrome (CRS), of AE grade 3 or 4 of study-drug_related events, incidence of Death and Secondary Primary Malignancies		6.5 years
Secondary	Tolerability : number of dose interruptions, dose reductions, and dose intensity, and study treatment discontinuation because of adverse events		6.5 years
Secondary	Health related quality of life as measured by the EQ-5D-5L		7 months
Secondary	Health related quality of life as measured by the EQ-5D-5L		12 months
Secondary	Health related quality of life as measured by the EQ-5D-5L		24 months